A detailed history of Legal & General Group PLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Legal & General Group PLC holds 238,816 shares of BCYC stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
238,816
Previous 238,816 -0.0%
Holding current value
$3.51 Million
Previous $5.42 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.58 - $27.24 $176,180 - $245,105
-8,998 Reduced 3.63%
238,816 $5.42 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $2.3 Million - $2.83 Million
114,746 Added 86.23%
247,814 $5.02 Million
Q1 2024

May 14, 2024

BUY
$16.75 - $26.1 $4,405 - $6,864
263 Added 0.2%
133,068 $3.31 Million
Q4 2023

Feb 15, 2024

BUY
$13.29 - $22.2 $536,145 - $895,592
40,342 Added 43.63%
132,805 $2.4 Million
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $242,919 - $320,433
12,207 Added 15.21%
92,463 $1.86 Million
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $1.27 Million - $1.92 Million
67,097 Added 509.89%
80,256 $2.05 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $52,572 - $82,377
2,626 Added 24.93%
13,159 $279,000
Q4 2022

Feb 14, 2023

BUY
$20.37 - $32.9 $28,518 - $46,060
1,400 Added 15.33%
10,533 $311,000
Q2 2022

Aug 22, 2022

SELL
$12.95 - $46.99 $27,622 - $100,229
-2,133 Reduced 18.93%
9,133 $154,000
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $48,384 - $71,757
1,206 Added 11.99%
11,266 $495,000
Q4 2021

Feb 14, 2022

SELL
$41.7 - $61.14 $6,171 - $9,048
-148 Reduced 1.45%
10,060 $612,000
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $60,847 - $96,310
2,177 Added 27.11%
10,208 $423,000
Q2 2021

Aug 12, 2021

BUY
$27.0 - $32.28 $216,837 - $259,240
8,031 New
8,031 $244,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.